A citation-based method for searching scientific literature

Adam N Rosenthal, Lindsay S M Fraser, Susan Philpott, Ranjit Manchanda, Matthew Burnell, Philip Badman, Richard Hadwin, Ivana Rizzuto, Elizabeth Benjamin, Naveena Singh, D Gareth Evans, Diana M Eccles, Andy Ryan, Robert Liston, Anne Dawnay, Jeremy Ford, Richard Gunu, James Mackay, Steven J Skates, Usha Menon, Ian J Jacobs. J Clin Oncol 2017
Times Cited: 72







List of co-cited articles
735 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
337
5

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Kelly Metcalfe, Henry T Lynch, William D Foulkes, Nadine Tung, Charmaine Kim-Sing, Olufunmilayo I Olopade, Andrea Eisen, Barry Rosen, Carrie Snyder, Shelley Gershman,[...]. JAMA Oncol 2015
62
6

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
554
5

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Jaya M Satagopan, Jeff Boyd, Noah D Kauff, Mark Robson, Lauren Scheuer, Steven Narod, Kenneth Offit. Clin Cancer Res 2002
110
5

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
5


Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Henry T Lynch, Susan L Neuhausen, Laura van 't Veer, Judy E Garber, Gareth R Evans, Steven A Narod, Claudine Isaacs, Ellen Matloff,[...]. J Clin Oncol 2004
698
5


Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention.
Jessica N McAlpine, Gillian E Hanley, Michelle M M Woo, Alicia A Tone, Nirit Rozenberg, Kenneth D Swenerton, C Blake Gilks, Sarah J Finlayson, David G Huntsman, Dianne M Miller. Am J Obstet Gynecol 2014
168
5

Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study.
William H Parker, Michael S Broder, Eunice Chang, Diane Feskanich, Cindy Farquhar, Zhimae Liu, Donna Shoupe, Jonathan S Berek, Susan Hankinson, JoAnn E Manson. Obstet Gynecol 2009
404
5

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
Celeste Leigh Pearce, Claire Templeman, Mary Anne Rossing, Alice Lee, Aimee M Near, Penelope M Webb, Christina M Nagle, Jennifer A Doherty, Kara L Cushing-Haugen, Kristine G Wicklund,[...]. Lancet Oncol 2012
530
5

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Harvey A Risch, John R McLaughlin, David E C Cole, Barry Rosen, Linda Bradley, Isabel Fan, James Tang, Song Li, Shiyu Zhang, Patricia A Shaw,[...]. J Natl Cancer Inst 2006
443
5

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
David W Kindelberger, Yonghee Lee, Alexander Miron, Michelle S Hirsch, Colleen Feltmate, Fabiola Medeiros, Michael J Callahan, Elizabeth O Garner, Robert W Gordon, Chandler Birch,[...]. Am J Surg Pathol 2007
707
5

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
321
5

Population-based, risk-stratified genetic testing for ovarian cancer risk: a focus group study.
S F Meisel, L Side, L Fraser, S Gessler, J Wardle, A Lanceley. Public Health Genomics 2013
19
21


Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
Catherine M Phelan, Karoline B Kuchenbaecker, Jonathan P Tyrer, Siddhartha P Kar, Kate Lawrenson, Stacey J Winham, Joe Dennis, Ailith Pirie, Marjorie J Riggan, Ganna Chornokur,[...]. Nat Genet 2017
134
5

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.
Sarah Jervis, Honglin Song, Andrew Lee, Ed Dicks, Patricia Harrington, Caroline Baynes, Ranjit Manchanda, Douglas F Easton, Ian Jacobs, Paul P D Pharoah,[...]. J Med Genet 2015
33
12

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Magali Olivier, David E Goldgar, Nayanta Sodha, Hiroko Ohgaki, Paul Kleihues, Pierre Hainaut, Rosalind A Eeles. Cancer Res 2003
293
5

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
387
5

Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.
Nicole Birrer, Carolina Chinchilla, Marcela Del Carmen, Don S Dizon. Am J Clin Oncol 2018
23
17

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Joanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, Pal Moller, Henry T Lynch, Susan L Neuhausen, Leigha Senter, Rochelle Demsky, William D Foulkes, Charis Eng,[...]. Breast Cancer Res Treat 2016
31
12

Low-dose aspirin use and the risk of ovarian cancer in Denmark.
L Baandrup, S K Kjaer, J H Olsen, C Dehlendorff, S Friis. Ann Oncol 2015
36
11

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Ranjit Manchanda, Rosa Legood, Matthew Burnell, Alistair McGuire, Maria Raikou, Kelly Loggenberg, Jane Wardle, Saskia Sanderson, Sue Gessler, Lucy Side,[...]. J Natl Cancer Inst 2014
97
5

Tubal ligation and the risk of ovarian cancer: review and meta-analysis.
D Cibula, M Widschwendter, O Májek, L Dusek. Hum Reprod Update 2011
158
5

The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Joanna B Madalinska, Marc van Beurden, Eveline M A Bleiker, Heiddis B Valdimarsdottir, Judith Hollenstein, Leon F Massuger, Katja N Gaarenstroom, Marian J E Mourits, René H M Verheijen, Eleonora B L van Dorst,[...]. J Clin Oncol 2006
142
5

Perineal Talc Use and Ovarian Cancer: A Systematic Review and Meta-Analysis.
Ross Penninkilampi, Guy D Eslick. Epidemiology 2018
30
13


The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Richard G Moore, Amy K Brown, M Craig Miller, Steven Skates, W Jeffrey Allard, Thorsten Verch, Margaret Steinhoff, Geralyn Messerlian, Paul DiSilvestro, C O Granai,[...]. Gynecol Oncol 2008
416
5


Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Katrina Armstrong, J Sanford Schwartz, Thomas Randall, Stephen C Rubin, Barbara Weber. J Clin Oncol 2004
110
5



A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA.
Qing Zhang, Guohong Hu, Qifeng Yang, Ruifen Dong, Xing Xie, Ding Ma, Keng Shen, Beihua Kong. Gynecol Oncol 2013
43
9

Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.
Yuxuan Wang, Lu Li, Christopher Douville, Joshua D Cohen, Ting-Tai Yen, Isaac Kinde, Karin Sundfelt, Susanne K Kjær, Ralph H Hruban, Ie-Ming Shih,[...]. Sci Transl Med 2018
83
5

Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Renée Turzanski Fortner, Antje Damms-Machado, Rudolf Kaaks. Gynecol Oncol 2017
34
11

A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.
Kathryn L Terry, Helena Schock, Renée T Fortner, Anika Hüsing, Raina N Fichorova, Hidemi S Yamamoto, Allison F Vitonis, Theron Johnson, Kim Overvad, Anne Tjønneland,[...]. Clin Cancer Res 2016
46
8

Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer.
Kevin M Elias, Wojciech Fendler, Konrad Stawiski, Stephen J Fiascone, Allison F Vitonis, Ross S Berkowitz, Gyorgy Frendl, Panagiotis Konstantinopoulos, Christopher P Crum, Magdalena Kedzierska,[...]. Elife 2017
54
7

A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.
Carolyn Y Fang, Carol Cherry, Karthik Devarajan, Tianyu Li, John Malick, Mary B Daly. Gynecol Oncol 2009
64
6

Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy.
Christos Iavazzo, Ioannis D Gkegkes, Nikolaos Vrachnis. J Turk Ger Gynecol Assoc 2016
12
33

BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles.
Moran Shapira, Hila Raanani, Baruch Feldman, Naama Srebnik, Sanaz Dereck-Haim, Daphna Manela, Masha Brenghausen, Liat Geva-Lerner, Eitan Friedman, Efrat Levi-Lahad,[...]. Fertil Steril 2015
49
8


Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, Siegal Sadetzki, Susan J Ramus, Beth Y Karlan, Diether Lambrechts, Evelyn Despierre, Daniel Barrowdale, Lesley McGuffog,[...]. JAMA 2012
366
5

Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Denise R Nebgen, Jean Hurteau, Laura L Holman, Andrea Bradford, Mark F Munsell, Beth R Soletsky, Charlotte C Sun, Gary B Chisholm, Karen H Lu. Gynecol Oncol 2018
29
13

Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
N A J Ryan, D G Evans, K Green, E J Crosbie. Gynecol Oncol 2017
38
10

Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.
Pål Møller, Toni T Seppälä, Inge Bernstein, Elke Holinski-Feder, Paulo Sala, D Gareth Evans, Annika Lindblom, Finlay Macrae, Ignacio Blanco, Rolf H Sijmons,[...]. Gut 2018
206
5

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
Nienke M van der Velde, Marian J E Mourits, Henriëtte J G Arts, Jacob de Vries, Beike K Leegte, Grieteke Dijkhuis, Jan C Oosterwijk, Geertruida H de Bock. Int J Cancer 2009
83
5

Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Phuong L Mai, Ana F Best, June A Peters, Rosamma M DeCastro, Payal P Khincha, Jennifer T Loud, Renée C Bremer, Philip S Rosenberg, Sharon A Savage. Cancer 2016
181
5

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Ranjit Manchanda, Shreeya Patel, Vladimir S Gordeev, Antonis C Antoniou, Shantel Smith, Andrew Lee, John L Hopper, Robert J MacInnis, Clare Turnbull, Susan J Ramus,[...]. J Natl Cancer Inst 2018
76
5

Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
Amy Finch, Patricia Shaw, Barry Rosen, Joan Murphy, Steven A Narod, Terence J Colgan. Gynecol Oncol 2006
258
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.